Ipsen: Accelerating profitable growth in pharma
Part One: Ipsen, a global pharmaceutical firm headquartered in France, was facing significant challenges, including regulatory setbacks and fierce competition, when David Loew assumed the role of CEO in 2020. The loss of exclusivity for Somatuline, Ipsen’s flagship cancer drug, added to the complexities. Tasked by the board, Loew aimed to lead Ipsen into a new era of profitable growth amid escalating competition. After thorough review during the Covid-19 pandemic, Loew and the executive team recognized the critical importance of the upcoming strategy. Ipsen Investors’ Day became the platform to unveil “Focus. Together. For Patients and Society,” the strategy shaping Ipsen’s trajectory toward ambitious 2025 targets. Despite pandemic disruptions, Loew was confident that Ipsen possessed the essential elements to embark on a new path of profitable growth. Part Two: Three years after launching the new strategy, David Loew concluded a meeting with the head of legal affairs, reflecting on the strategy’s journey. Structured around four pillars, the strategy prioritized patient-centricity, a sustainable pipeline, improved efficiency and operational excellence through collaboration and a diverse workforce. Ipsen’s ambition was to be an adaptable force, creating lasting value. While Ipsen made significant strides in executing the strategy, recognizing market acknowledgment, critical questions persisted. These revolved around geographic footprint, digital integration, ongoing cultural transformation and the accelerated development of key products alongside acquisitions to fortify the pipeline. Loew prepared for a two-day session with the executive team to capitalize on successes and chart the way forward to future-proof the company.
- Understand Ipsen’s strategic transformation: Gain insights into its transformation journey, from its historical roots to its current strategic direction under David Loew’s leadership.
- Understand Ipsen’s competitive environment and the macro factors that have shaped the pharma industry and will influence its future evolution.
- Explore the need for a mid-sized global pharma to design a new strategy in view of likely future disruptions to the sector.
- Explore strategy design in a highly competitive industry.
- Think holistically about how to approach the design of a multi-year corporate strategy.
Ipsen, Healthcare, Biopharmaceuticals, Healthcare, Pharmaceuticals
2019-2024
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications

Today’s workforce often includes a mix of permanent employees, freelancers, and outside contractors – but even organizations with mostly external workforces or highly autonomous workforces need proximity to succeed over the long term. Here are fou...

Set in 2024, the case describes the trajectory of Nike's success and how it had recently lost its way. The company was experiencing its worst slump in more than 10 years. Since 2020, CEO Donahoe oversaw a significant shift away from wholesale, wit...

Corporate leaders must stop being passive spectators and actively shape geopolitical outcomes to drive global competitiveness and collaboration.

This brief case exercise presents an increasingly common business scenario: An established player acquires a small, agile start-up to re-energize its value proposition. In this case, established global beauty giant UrbanLuxe acquires beauty start-...

Trump’s unconventional negotiation strategy reveals how game theory in negotiations can shape power, commitment, and outcomes before talks begin.

In an age that prizes agility, breaking up is a strategy rather than a surrender, argues IMD’s Salvatore Cantale, as CFOs step forward as architects of value in the de-conglomeration era.

What does it take to move from CFO to CEO? Four top executives share candid lessons on leadership, risk, growth, and redefining the finance role.
In an increasingly uncertain world, how do companies plan for the long term? Take this short quiz to test your knowledge of future readiness, and read on for insights from future-ready companies.

Use our AI Trust Checklist to avoid bias, hallucinations, and deepfakes. Practical tips to build trust in your AI systems.
Shenzhen Power-Solution (SPS), founded in 2009 in China as an entrepreneurial venture, disrupted traditional lighting markets in African villages with its flagship product, Candles Killer. This solar lamp, priced under $5, replaces hazardous keros...
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications